“…Five of 8 studies using 2000/2007 WHO guidelines demonstrated improved PFS after adjuvant EBRT (Table 4). 24,26,37,46,48,59,77,81 However, Grade II meningiomas represent a heterogeneous group of tumors, 47,51,53 and not all patients may benefit equally from adjuvant EBRT. 24,26,77,85 In particular, histological necrosis has been shown to be a strong predictor of radioresistance in a large study by Sun et al, 77 such that the efficacy of adjuvant EBRT may be limited in AMs with necrosis (EBM Level 3, Grade 2C recommendation).…”